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Dear Editor, 54 
Common management options for Graves’ disease (GD) include medical treatment, 55 
radioactive iodine (RAI) ablation or surgery. Thionamides (carbimazole, methimazole and 56 
propylthiouracil) are the first-line medical treatment of GD. Due to potential hepatotoxicity, their 57 
use in the setting of underlying hepatic disease can be challenging. For such cases and if 58 
thyroidectomy or RAI cannot be rapidly implemented, alternative medical strategies are not 59 
well-established. 60 
We report the case of a 28-year-old Caucasian female diagnosed with type I autoimmune 61 
hepatitis (AIH) with severely altered liver function tests (alanine aminotransferase of 1437 U/l, 62 
total bilirubin of 286 µmol/l).An undetectable TSH prompted a targeted history that revealed 63 
recent restlessness, rapid heartbeat and increased stool frequency. Free thyroxine (fT4) and free 64 
triiodothyronine (fT3) were more than 2-fold increased. Ultrasonography showed a normally 65 
sized but heterogeneous thyroid with increased vascularity. Autoantibodies against the 66 
thyrotropin receptor (TRAb) were strongly positive; a diagnosis of GD was made. Due to the 67 
AIH, oral prednisone was started at 50 mg/day, with rapid improvement of hepatic function, 68 
allowing for progressive tapering after 2 weeks with concomitant introduction of azathioprine. 69 
Given the severe hepatitis, thionamides were withheld in accordance with ATA guidelines 70 
recommending caution in case of more than 5-fold transaminase elevation. Propranolol and low 71 
dose cholestyramine were prescribed for 3 weeks. A rapid decrease of both fT4 and fT3 was 72 
observed as soon as 48 hours after glucocorticoid (GC) initiation. After 1 month of 73 
immunosuppressive treatment, liver function tests, fT4 and fT3 were normal. The TRAb titer 74 
progressively decreased, becoming negative at 6 months of treatment (Fig. 1).  75 
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Somewhat paradoxically, GD is one of the few autoimmune diseases for which GCs are 76 
not part of the first-line therapeutic choices mainly due to fear of complications from long-term 77 
administration. Nevertheless, GCs are routinely used in the management of thyroid storm and 78 
have proven effective in combination with carbimazole for resistant thyrotoxicosis. 79 
Improvement of Graves’ thyrotoxicosis with GCs was first reported in 1965 by Werner et 80 
al. who treated 5 GD patients with prednisone 100 mg/day (1). In contrast to our case, some 81 
patients in that study had received prior treatment with propylthiouracil. In another study of GD 82 
patients (2), the rapid decrease of both T4 and T3 levels by short-term dexamethasone suggested 83 
that the GC’s benefit is mediated not only by inhibiting the conversion of T4 to T3 in peripheral 84 
tissues, but also by reducing thyroid hormone secretion; the present case suggests GC-mediated 85 
reduction of TRAb as a potential contributing mechanism. An alteration of the TRAb function 86 
and/or type is another possibility, which we were unable to explore because a TRAb bioassay 87 
was not performed. Data on the link between GCs and TRAb are scarce. Adding an 88 
intrathyroidal dexamethasone injection to methimazole significantly reduced TRAb levels in 89 
newly diagnosed GD patients in one study (3). Conversely, Kahaly et al. (4) detected a 90 
significant decrease of TRAb in patients with Graves' orbitopathy treated by intravenous but not 91 
oral GC for 12 weeks. Interestingly, baseline TRAb levels were higher in the latter study, 92 
possible suggesting that oral GC might be less effective when the autoimmune load is higher. 93 
Other potential explanations for the notable response of TRAb in our case might be the slower 94 
tapering, longer treatment and/or the addition of azathioprine. 95 
We chose not to offer immediate definitive treatment to our patient. The risk of 96 
immediate total thyroidectomy was estimated too high in a context of acute hepatitis, while RAI 97 
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was considered a suboptimal choice given the risk for transient worsening of hyperthyroidism 98 
and the possible delayed beneficial effect. 99 
In the absence of an iodine/pertechnetate uptake and scintigraphy, a painless thyroiditis 100 
with subsequent normalization of thyroid function cannot be formally excluded. Nevertheless, 101 
the ultrasonographic findings and the frankly positive TRAb, measured by a third generation 102 
assay render this diagnosis much less likely. Lastly, spontaneous remission may occur, such as in 103 
patients with alemtuzumab-induced GD. However, the very rapid pace of improvement of 104 
thyroid function as soon as 48 hours after GC initiation argues against spontaneous remission.  105 
In conclusion, this case highlights a potential role for GCs in selected GD patients with 106 
contraindications to thionamides who are not eligible for immediate definitive treatment. The 107 
onset of GC action in our patient appeared to be rapid, with likely multiple mechanisms, 108 
including suppression of T4 conversion to T3 and reduction of TRAb-mediated thyrocyte 109 
stimulation. Our observations warrant confirmation in the setting of a clinical trial; treatment 110 
with non-GC immunosuppressants could also be explored.  111 
  112 
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FIGURE 1 154 
 155 
 156 
FIGURE 1 LEGEND 157 
Graphical representation of thyroid function tests (A) and thyroid antibodies (B) in different 158 
timepoints of the patient’s management according to the medications administered (C). Notably, 159 
no thionamide treatment was introduced due to concomitant autoimmune hepatitis. A rapid 160 
response to prednisone was noted with subsequent normalization of FT4 and FT3 at one month 161 
of treatment. Despite tapering of glucocorticoids, the thyroid response was sustained under 162 
azathioprine, and TSH and TRAb were normalized at 6 months of treatment. Normal ranges for 163 
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the different parameters are the following: TSH, 0.27-4.20 mUI/l; FT4, 12-22 pmol/l; FT3, 3.1-164 
6.8 pmol/l, TRAb, < 1.75 UI/l, TPOAb, < 34 kUI/l; TgAb < 33 kUI/l.  165 
Abbreviations: GC, glucocorticoids; FT4, free thyroxine; FT3, free triiodothyronine; M1, month 166 
1; M2, month 2; M4, month 4; M6, month 6; qd, once daily; T0, right before onset of treatment; 167 
tid, three times daily; TgAb, thyroglobulin antibodies; TPOAb, thyroid peroxidase antibodies; 168 
TRAb, thyrotropin receptor antibodies; TSH, thyrotropin; W2, week 2. 169 
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